Rapid communication Open Access
Like 0


A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries’ programmatic deliberations.


Article metrics loading...

Loading full text...

Full text loading...



  1. Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341-53.  https://doi.org/10.1016/S2213-2600(22)00414-3  PMID: 36372082 
  2. Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21(11):734-49.  https://doi.org/10.1038/s41579-023-00919-w  PMID: 37438492 
  3. Martinón-Torres F, Navarro-Alonso JA, Garcés-Sánchez M, Soriano-Arandes A. The path towards effective respiratory syncytial virus immunization policies: recommended actions. Arch Bronconeumol. 2023;59(9):581-8.  https://doi.org/10.1016/j.arbres.2023.06.006  PMID: 37414639 
  4. Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018. BMC Infect Dis. 2023;23(1):385.  https://doi.org/10.1186/s12879-023-08358-x  PMID: 37291530 
  5. Martinón-Torres F, Carmo M, Platero L, Drago G, López-Belmonte JL, Bangert M, et al. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study. BMC Infect Dis. 2022;22(1):759.  https://doi.org/10.1186/s12879-022-07745-0  PMID: 36175846 
  6. Mao Z, Li X, Dacosta-Urbieta A, Billard MN, Wildenbeest J, Korsten K, et al. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe. Vaccine. 2023;41(16):2707-15.  https://doi.org/10.1016/j.vaccine.2023.03.024  PMID: 36941154 
  7. McGinley JP, Lin GL, Öner D, Golubchik T, O’Connor D, Snape MD, et al. Clinical and viral factors associated with disease severity and subsequent wheezing in infants with respiratory syncytial virus infection. J Infect Dis. 2022;226(Suppl 1):S45-54.  https://doi.org/10.1093/infdis/jiac163  PMID: 35902389 
  8. Johannesen CK, van Wijhe M, Tong S, Fernández LV, Heikkinen T, van Boven M, et al. Age-specific estimates of respiratory syncytial virus-associated hospitalizations in 6 European countries: a time series analysis. J Infect Dis. 2022;226(Suppl 1):S29-37.  https://doi.org/10.1093/infdis/jiac150  PMID: 35748871 
  9. Ares-Gomez S, Mallah N, Pardo-Seco J, Nartallo-Penas V, Mirás-Carballal S, Rodriguez-Tenreiro-Sánchez C, et al. Improving influenza vaccine acceptance in children leveraging on COVID-19 vaccination lessons. Arch Bronconeumol. 2023;59(8):531-3.  https://doi.org/10.1016/j.arbres.2023.03.011  PMID: 37003883 
  10. Galician RSV immunoprophylaxis campaign. Respira tranquilo. [Breathe easy]. Santiago de Compostela: Council of Galicia. [Accessed: 4 Nov 2023]. Available from: https://www.sergas.es/Saude-publica/INMUNIZACION-FRONTE-AO-VIRUS-RESPIRATORIO-SINCITIAL
Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error